Source comparison
GHRP-2 Acetate: Growth Hormone Releasing Peptide-2 Comparison
GHRP-2 Acetate D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂ GHS-R1a (ghrelin receptor) 9.3 ± 2.1 ng/mL 20–30 minutes Minimal at standard doses Gold standard for pulsatile GH research. High receptor affinity, minimal off-target effects, acetate salt prevents degradation
This comparison does not assign a generated winner or score.
- GHRP-2 Acetate
- D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂
- GHS-R1a (ghrelin receptor)
- 9.3 ± 2.1 ng/mL
- 20–30 minutes
- Minimal at standard doses
- Gold standard for pulsatile GH research. High receptor affinity, minimal off-target effects, acetate salt prevents degradation
- GHRP-6
- His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂
- GHS-R1a
- 7.8 ± 1.9 ng/mL
- 15–25 minutes
- Strong. Dose-dependent appetite stimulation
- Earlier-generation secretagogue. Effective but orexigenic side effect limits utility in metabolic studies
- Ipamorelin
- Aib-His-D-2-Nal-D-Phe-Lys-NH₂
- 5.2 ± 1.4 ng/mL
- 2 hours
- None
- Longest half-life among GHRPs. Lower GH peak but extended duration, preferred for sustained-release protocols
- Hexarelin
- His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂
- GHS-R1a + cardiac receptors
- 11.1 ± 2.8 ng/mL
- 70 minutes
- Moderate
- Highest GH response but significant prolactin/cortisol elevation. Cardiac receptor binding raises concerns in prolonged studies
- Endogenous Ghrelin
- 28-amino-acid peptide (acylated at Ser3)
- Variable (6–15 ng/mL)
- 9–13 minutes (acylated form)
- Very strong
- Physiological secretagogue. Rapid degradation limits research utility unless continuously infused